MIGS vs Glaucoma Drops in Plano: When to Consider Each

Glaucoma drops work for many patients. The problem is not that drops are bad.

The problem is that drops only work when they are used correctly, tolerated well, affordable, and strong enough to keep eye pressure in a safe range.

A strong glaucoma-drop alternative conversation should not skip SLT, medication changes, or monitoring just to reach surgery. It should compare daily drops, in-office no-incision laser, sustained-release medicine, drainage-based MIGS, cataract timing, and traditional surgery referral when disease is advanced. That wider ladder gives patients a clearer answer than a simple device list.

What glaucoma drops are trying to do

Glaucoma damages the optic nerve, often because pressure inside the eye is higher than the nerve can safely tolerate. Drops are prescribed to lower intraocular pressure by improving fluid drainage, reducing fluid production, or both.

When drops work well, they can be excellent.

Ocular hypertension is a risk question first

The first step is separating ocular hypertension from confirmed glaucoma. Ocular hypertension means the pressure is higher than expected but optic nerve damage or visual field loss has not been proven. That difference matters because some patients need monitoring, while higher-risk patients may benefit from drops or SLT before surgery is discussed.

A useful visit should review central corneal thickness, repeat pressure readings, optic nerve OCT, visual fields, drainage-angle anatomy, family history, age, steroid use, prior eye injury, and whether cataract timing changes the pressure plan. Durysta, iDose, drainage-based MIGS, or traditional glaucoma surgery should not be chosen from a pressure number alone.

But many patients struggle with:

• Burning, redness, or irritation.
• Forgetting doses.
• Trouble placing drops accurately.
• Multiple bottles with different schedules.
• Insurance formulary changes.
• Cost.
• Worsening pressure despite treatment.

Those problems matter because glaucoma care is long-term. A plan that looks good on paper but fails in daily life may not protect the optic nerve well enough.

What MIGS means

MIGS stands for minimally invasive glaucoma surgery; some practices call the same category micro-invasive glaucoma surgery or M.I.G.S. It is not one procedure. It is a family of smaller glaucoma procedures designed to lower pressure with less tissue disruption than older traditional glaucoma surgeries.

At Visionary Eye Surgery, the MIGS family includes:

• iStent.
• Hydrus Microstent.
• Goniotomy.
• Canaloplasty.
• Durysta.
• iDose.

Some MIGS procedures improve the eye's drainage pathway with glaucoma stents or angle-based treatment. Some deliver medication inside the eye. Some are often combined with cataract surgery. The correct choice depends on glaucoma type, pressure target, eye anatomy, medication history, and cataract status.

MIGS is not always a replacement for drops

This point matters for trust.

MIGS can reduce drop burden for many patients, but it does not guarantee that every patient will stop drops forever. Some patients reduce the number of drops. Some stop drops for a period of time. Some still need medication afterward.

The goal is not a slogan. The goal is lower, steadier eye pressure with a plan the patient can actually follow.

When a glaucoma drops alternative should be discussed

Ask about MIGS or sustained-release medication options if:

• Your eye pressure is not controlled despite drops.
• Your drops cause redness, burning, allergy, or surface irritation.
• You miss doses because the schedule is hard.
• You cannot reliably place the drop in the eye.
• Cost or insurance changes make treatment unstable.
• You also have cataracts and may benefit from combining cataract surgery with a MIGS procedure.
• You have open-angle glaucoma or ocular hypertension and want to understand every pressure-lowering option.

The conversation should happen before the eye is in trouble, not after years of avoidable progression.

Where Durysta and iDose fit

Durysta and iDose TR are different from drainage-stent procedures because they deliver medication inside the eye.

That can be helpful for patients who respond to medication but struggle with daily drops.

They are not the same product. Durysta is biodegradable, designed to release medication for about 3 to 4 months, and currently limited to a single implant per eye without retreatment. iDose TR is an anchored travoprost implant with official patient information describing pressure control shown up to 3 years; readministration is a separate decision that requires corneal endothelial testing and ongoing monitoring. That difference matters when a patient wants to reduce daily drops without losing the pressure control needed to protect the optic nerve.

The key questions are:

• Is the glaucoma type appropriate?
• Is the eye anatomy suitable?
• What pressure target are we trying to reach?
• Has the patient responded to this medication class before?
• Is the corneal endothelium healthy enough for an intracameral implant?
• Is the goal short-term drop relief, longer-acting medication delivery, or drainage-based pressure reduction?
• How will pressure and optic nerve stability be monitored afterward?

These are not cosmetic convenience procedures. They are medical decisions built around optic nerve protection.

How to read "drop-free" glaucoma claims

"Drop-free" is useful shorthand, but it can be misleading if it sounds like every patient stops drops forever.

The better conversation is fewer-drop planning. Some patients may reduce or pause daily drops after SLT, Durysta, iDose TR, iStent, Hydrus, goniotomy, or canaloplasty. Other patients still need one or more drops afterward because glaucoma is chronic and the optic nerve still needs a safe pressure range.

• Does the page separate sustained-release medication from drainage-based MIGS?
• Does it explain Durysta as single-administration per eye under current labeling?
• Does it explain iDose TR candidacy, corneal endothelial testing, and readministration monitoring?
• Does it say when advanced glaucoma may need trabeculectomy, tube shunt surgery, or fellowship-glaucoma referral instead of MIGS?

That is the difference between a procedure list and a pressure plan.

When iStent, Hydrus, goniotomy, or canaloplasty fit

Drainage-based MIGS procedures are usually considered when improving outflow can help lower pressure.

Some options are commonly paired with cataract surgery because the eye is already being treated surgically. Others may be considered based on angle anatomy and disease pattern.

The best procedure depends on what is limiting drainage:

• The trabecular meshwork.
• Schlemm's canal.
• The collector channels.
• Medication burden.
• Cataract timing.
• Pressure target.

This is why a MIGS consultation should include gonioscopy, pressure history, optic nerve imaging, visual fields, medication review, and cataract evaluation.

When another glaucoma review may help

A second opinion can help when the pressure target, evidence of progression, medication burden, or reason for a particular procedure remains unclear. See our glaucoma second-opinion guide for the records to bring and the questions a useful review should answer.

Related resources

• MIGS glaucoma surgery
• Durysta
• iDose
• Glaucoma pressure-goal care
• Glaucoma overview
• Glaucoma exam guide
• Glaucoma second-opinion guide
• MIGS recovery timeline

Bottom line

Glaucoma drops are still useful. MIGS is not a magic replacement for every patient.

But if drops are irritating, hard to use, expensive, or not controlling pressure well enough, it is reasonable to ask whether MIGS, Durysta, iDose, or another pressure-lowering option could reduce the burden.